TEVA
Teva Pharmaceutical·NYSE
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TEVA
Teva Pharmaceutical Industries Limited
The largest generic drug manufacturer and one of the largest pharmaceutical company in the world
Pharmaceutical
02/13/1944
05/30/2012
New York Stock Exchange
33,950
12-31
Depository Receipts (Ordinary Shares)
124 Dvora HaNevi’a St., Tel Aviv, ISRAEL, 6944020
Manufacturers of generic and innovative drugs.
Teva Pharmaceutical Industries Limited was incorporated in Israel on February 13, 1944. The company is a global biopharmaceutical company with a significant generic drug business, operating in approximately 57 markets worldwide. It focuses on innovation in the fields of neuroscience and immunology, while offering complex generic, biosimilar and pharmacy brands to meet the needs of patients.
Company Financials
EPS
TEVA has released its 2025 Q4 earnings. EPS was reported at 0.96, versus the expected 0.65, beating expectations. The chart below visualizes how TEVA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TEVA has released its 2025 Q4 earnings report, with revenue of 4.71B, reflecting a YoY change of 11.40%, and net profit of 481.00M, showing a YoY change of 274.91%. The Sankey diagram below clearly presents TEVA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
